Amarna Therapeutics B.V.
J.H. Oortweg 21
6 articles about Amarna Therapeutics B.V.
BioSpace Movers & Shakers, Nov. 6
11/6/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace Movers & Shakers, Sept. 4
9/4/2020Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace Global Roundup, Oct. 17
10/17/2019Companies from across the globe provide business and pipeline updates.
Amarna Therapeutics Raises €10 million to Progress lead Development Candidate into Clinical Trials and Appoints a new Supervisory Board
Amarna Therapeutics, a privately held biotechnology company developing a next-generation SV40-based gene delivery vector platform named SVac that promises to transform gene-replacement and immunotherapy across many disease areas, today announced that it has raised €10 million.
Amarna Therapeutics B.V. Teaming Up with Austrian CBmed In The Development Of Immunotherapies
Amarna Therapeutics B.V. And TNO Announce SVac Research And Development Partnership